Table 3. In vitro sensitivity to p53 SMWC of ALDHbright cells present in tumor cell lines derived from tumors of MCA mice treated with p53 SMWC.
| Tumor cell lines | Untreated control | CP-31398 treated | PRIMA-1 treated | |||||
|---|---|---|---|---|---|---|---|---|
| ALDH+ cells | ALDHbrightcells | Bulk cells | ALDH+ cells | ALDHbrightcells | Bulk cells | ALDH+ cells | ALDHbright cells | |
| MCA 17.4 (untreated) | 2.3% | 0.03% | −80% | −95% | −95% | −68% | −85% | −66% |
| MCA 1.5 (CP-31398) | 3.1% | 0.09% | −75% | −88% | −66% | −73% | −75% | −70% |
| MCA 5.5 (PRIMA-1) | 3.0% | 0.96% | −71% | −83% | −75% | −75% | −95% | −90% |
Low passage cell lines (≤ 3) derived from tumors harvested from p53 SMWC-treated MCA mice were analyzed for sensitivity to treatment with CP-31398 (20 μM) and PRIMA-1 (32 μM). In addition to determining cytotoxicity to the bulk population of tumor cells, the treated cells were analyzed for ALDHpositive and ALDHbright cell content.
Abbreviations: MCA, methylcholantrene; SMWC, small molecular weight compound.